SRR1516076
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- APICAL_SURFACE+0.380
- KRAS_SIGNALING_DN+0.370
- ALLOGRAFT_REJECTION+0.320
- G2M_CHECKPOINT+0.320
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- INTERFERON_ALPHA_RESPONSE+0.270
- MYOGENESIS+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.340
- TGF_BETA_SIGNALING-0.290
- OXIDATIVE_PHOSPHORYLATION-0.200
- PEROXISOME-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.190
- BILE_ACID_METABOLISM-0.170
- MYC_TARGETS_V1-0.170
- UV_RESPONSE_DN-0.160
- ANDROGEN_RESPONSE-0.140
- MYC_TARGETS_V2-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516078 | — | — | 0.807 |
| 2 | R317 | — | — | 0.761 |
| 3 | BS_7BW0YRPY | Embryonal tumors | — | 0.756 |
| 4 | TCGA-GU-A764-01A-11R-A352-07 | — | — | 0.755 |
| 5 | SRR8943031 | — | — | 0.754 |
| 6 | MNG304 | — | — | 0.746 |
| 7 | TCGA-BT-A42E-01A-11R-A23W-07 | — | — | 0.733 |
| 8 | SRR2778056 | — | — | 0.730 |
| 9 | MDT-AP-1133 | Med | Medulloblastoma | 0.725 |
| 10 | R50 | — | — | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |